MINI FUTURE LONG - GILEAD SCIENCES | Market Closed - Börse Stuttgart 20:43:17 03/05/2024 BST | ||
| 0.72 EUR | -7.69% |
|
| Current month | -5.26% | ||
| 1 month | -45.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/05/24 | 0.72 | -7.69% | 0 |
| 02/05/24 | 0.78 | +2.63% | 0 |
| 30/04/24 | 0.76 | -8.43% | 0 |
| 29/04/24 | 0.83 | +1.22% | 0 |
| 26/04/24 | 0.82 | +5.13% | 0 |
Delayed Quote Börse Stuttgart
Last update May 03, 2024 at 08:43 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PR9F6Y |
| ISIN | DE000PR9F6Y9 |
| Date issued | 01/09/2017 |
| Strike | 56.83 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.61 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.44 € |
|---|---|
| Lowest since issue | 0.35 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.78
USD
Average target price
83.46
USD
Spread / Average Target
+28.84%
- Stock Market
- Certificates
- Certificat
